Detection and treatment of Trypanosoma cruzi: a patent review (2011-2015)

Introduction: Trypanosoma cruzi is the etiologic agent of American trypanosomiasis (Chagas disease), which is one of the important parasitic diseases worldwide. The number of infected people with T. cruzi diminished from 18 million in 1991 to 6 million in 2010, but it is still the most prevalent par...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Rodríguez, Juan Bautista, Szajnman, Sergio Hernán
Publicado:	2016
Materias:	antiparasitic agents Chagas disease diagnosis drug discovery drug treatment Trypanosoma cruzi benznidazole boron derivative cysteine proteinase geranyltransferase hydroxymethylglutaryl coenzyme A reductase iron superoxide dismutase methyltransferase methyltransferase inhibitor nifurtimox phosphatidylinositol 3 kinase sialidase squalene monooxygenase squalene synthase squalene synthase inhibitor sterol 14alpha demethylase sterol 14alpha demethylase inhibitor trypanothione antitrypanosomal agent diagnostic procedure human long term care nonhuman parasite identification parasite serodiagnosis patent Review unspecified side effect animal drug design drug effects drug resistance isolation and purification parasitemia parasitology Animals Chagas Disease Drug Design Drug Resistance Humans Parasitemia Patents as Topic Trypanocidal Agents
Acceso en línea:	https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_13543776_v26_n9_p993_Rodriguez http://hdl.handle.net/20.500.12110/paper_13543776_v26_n9_p993_Rodriguez
Aporte de:	Biblioteca Digital - Facultad de Ciencias Exactas y Naturales (UBA) de Universidad de Buenos Aires

id	paper:paper_13543776_v26_n9_p993_Rodriguez
record_format	dspace
spelling	paper:paper_13543776_v26_n9_p993_Rodriguez2023-06-08T16:11:06Z Detection and treatment of Trypanosoma cruzi: a patent review (2011-2015) Rodríguez, Juan Bautista Szajnman, Sergio Hernán antiparasitic agents Chagas disease diagnosis drug discovery drug treatment Trypanosoma cruzi benznidazole boron derivative cysteine proteinase geranyltransferase hydroxymethylglutaryl coenzyme A reductase iron superoxide dismutase methyltransferase methyltransferase inhibitor nifurtimox phosphatidylinositol 3 kinase sialidase squalene monooxygenase squalene synthase squalene synthase inhibitor sterol 14alpha demethylase sterol 14alpha demethylase inhibitor trypanothione antitrypanosomal agent Chagas disease diagnostic procedure human long term care nonhuman parasite identification parasite serodiagnosis patent Review Trypanosoma cruzi unspecified side effect animal drug design drug effects drug resistance isolation and purification parasitemia parasitology Trypanosoma cruzi Animals Chagas Disease Drug Design Drug Resistance Humans Parasitemia Patents as Topic Trypanocidal Agents Trypanosoma cruzi Introduction: Trypanosoma cruzi is the etiologic agent of American trypanosomiasis (Chagas disease), which is one of the important parasitic diseases worldwide. The number of infected people with T. cruzi diminished from 18 million in 1991 to 6 million in 2010, but it is still the most prevalent parasitic disease in the Americas. The existing chemotherapy is still deficient and based on two drugs: nifurtimox and benznidazole, which are not FDA-approved in the United States. Areas covered: This review covers the current and future directions of Chagas disease chemotherapy based on drugs that interfere with relevant metabolic pathways. This article also illustrates the challenges of diagnosis, which in recent infections, is only detected when the parasitemia is high (direct detection); whereas, in the chronic phase is reached after multiple serological tests. Expert opinion: The current chemotherapy is associated with long term treatments and severe side effects. Nifurtimox and benznidazole are able to cure at least 50% of recent infections. Nevertheless, they suffer from major drawbacks: selective drug sensitivity on different T. cruzi strains and serious side effects. The aim of this review is focused on presenting an up-to-date status of the chemotherapy and diagnosis. © 2016 Informa UK Limited, trading as Taylor & Francis Group. Fil:Rodriguez, J.B. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales; Argentina. Fil:Szajnman, S.H. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales; Argentina. 2016 https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_13543776_v26_n9_p993_Rodriguez http://hdl.handle.net/20.500.12110/paper_13543776_v26_n9_p993_Rodriguez
institution	Universidad de Buenos Aires
institution_str	I-28
repository_str	R-134
collection	Biblioteca Digital - Facultad de Ciencias Exactas y Naturales (UBA)
topic	antiparasitic agents Chagas disease diagnosis drug discovery drug treatment Trypanosoma cruzi benznidazole boron derivative cysteine proteinase geranyltransferase hydroxymethylglutaryl coenzyme A reductase iron superoxide dismutase methyltransferase methyltransferase inhibitor nifurtimox phosphatidylinositol 3 kinase sialidase squalene monooxygenase squalene synthase squalene synthase inhibitor sterol 14alpha demethylase sterol 14alpha demethylase inhibitor trypanothione antitrypanosomal agent Chagas disease diagnostic procedure human long term care nonhuman parasite identification parasite serodiagnosis patent Review Trypanosoma cruzi unspecified side effect animal drug design drug effects drug resistance isolation and purification parasitemia parasitology Trypanosoma cruzi Animals Chagas Disease Drug Design Drug Resistance Humans Parasitemia Patents as Topic Trypanocidal Agents Trypanosoma cruzi
spellingShingle	antiparasitic agents Chagas disease diagnosis drug discovery drug treatment Trypanosoma cruzi benznidazole boron derivative cysteine proteinase geranyltransferase hydroxymethylglutaryl coenzyme A reductase iron superoxide dismutase methyltransferase methyltransferase inhibitor nifurtimox phosphatidylinositol 3 kinase sialidase squalene monooxygenase squalene synthase squalene synthase inhibitor sterol 14alpha demethylase sterol 14alpha demethylase inhibitor trypanothione antitrypanosomal agent Chagas disease diagnostic procedure human long term care nonhuman parasite identification parasite serodiagnosis patent Review Trypanosoma cruzi unspecified side effect animal drug design drug effects drug resistance isolation and purification parasitemia parasitology Trypanosoma cruzi Animals Chagas Disease Drug Design Drug Resistance Humans Parasitemia Patents as Topic Trypanocidal Agents Trypanosoma cruzi Rodríguez, Juan Bautista Szajnman, Sergio Hernán Detection and treatment of Trypanosoma cruzi: a patent review (2011-2015)
topic_facet	antiparasitic agents Chagas disease diagnosis drug discovery drug treatment Trypanosoma cruzi benznidazole boron derivative cysteine proteinase geranyltransferase hydroxymethylglutaryl coenzyme A reductase iron superoxide dismutase methyltransferase methyltransferase inhibitor nifurtimox phosphatidylinositol 3 kinase sialidase squalene monooxygenase squalene synthase squalene synthase inhibitor sterol 14alpha demethylase sterol 14alpha demethylase inhibitor trypanothione antitrypanosomal agent Chagas disease diagnostic procedure human long term care nonhuman parasite identification parasite serodiagnosis patent Review Trypanosoma cruzi unspecified side effect animal drug design drug effects drug resistance isolation and purification parasitemia parasitology Trypanosoma cruzi Animals Chagas Disease Drug Design Drug Resistance Humans Parasitemia Patents as Topic Trypanocidal Agents Trypanosoma cruzi
description	Introduction: Trypanosoma cruzi is the etiologic agent of American trypanosomiasis (Chagas disease), which is one of the important parasitic diseases worldwide. The number of infected people with T. cruzi diminished from 18 million in 1991 to 6 million in 2010, but it is still the most prevalent parasitic disease in the Americas. The existing chemotherapy is still deficient and based on two drugs: nifurtimox and benznidazole, which are not FDA-approved in the United States. Areas covered: This review covers the current and future directions of Chagas disease chemotherapy based on drugs that interfere with relevant metabolic pathways. This article also illustrates the challenges of diagnosis, which in recent infections, is only detected when the parasitemia is high (direct detection); whereas, in the chronic phase is reached after multiple serological tests. Expert opinion: The current chemotherapy is associated with long term treatments and severe side effects. Nifurtimox and benznidazole are able to cure at least 50% of recent infections. Nevertheless, they suffer from major drawbacks: selective drug sensitivity on different T. cruzi strains and serious side effects. The aim of this review is focused on presenting an up-to-date status of the chemotherapy and diagnosis. © 2016 Informa UK Limited, trading as Taylor & Francis Group.
author	Rodríguez, Juan Bautista Szajnman, Sergio Hernán
author_facet	Rodríguez, Juan Bautista Szajnman, Sergio Hernán
author_sort	Rodríguez, Juan Bautista
title	Detection and treatment of Trypanosoma cruzi: a patent review (2011-2015)
title_short	Detection and treatment of Trypanosoma cruzi: a patent review (2011-2015)
title_full	Detection and treatment of Trypanosoma cruzi: a patent review (2011-2015)
title_fullStr	Detection and treatment of Trypanosoma cruzi: a patent review (2011-2015)
title_full_unstemmed	Detection and treatment of Trypanosoma cruzi: a patent review (2011-2015)
title_sort	detection and treatment of trypanosoma cruzi: a patent review (2011-2015)
publishDate	2016
url	https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_13543776_v26_n9_p993_Rodriguez http://hdl.handle.net/20.500.12110/paper_13543776_v26_n9_p993_Rodriguez
work_keys_str_mv	AT rodriguezjuanbautista detectionandtreatmentoftrypanosomacruziapatentreview20112015 AT szajnmansergiohernan detectionandtreatmentoftrypanosomacruziapatentreview20112015
_version_	1768546034427887616

Detection and treatment of Trypanosoma cruzi: a patent review (2011-2015)

Ejemplares similares